Document is current
Any future updates will be listed below
-
Authors
Lopci, Egesta https://orcid.org/0000-0001-9732-1094
Lazzeri, Massimo
Saita, Alberto
Saitta, Cesare
Disconzi, Luca
Colombo, Piergiuseppe
Fasulo, Vittorio
Tarullo, Gianluca
Vuono, Elisa
Peschechera, Roberto
Zanca, Roberta
Jandric, Jelena
Sposta, Federica Mrakic
Scapaticci, Emanuele
Paciotti, Marco
Hurle, Rodolfo
Benetti, Alessio
Avolio, Pier Paolo
Cieri, Miriam
Zandegiacomo, Silvia
Pasini, Luisa
Casale, Paolo
Guazzoni, Giorgio
Balzarini, Luca
Laghi, Andrea
Buffi, Nicolò Maria
Lughezzani, Giovanni
-
Funding
Funding for this research was provided by:
Ministero della Salute (GR-2018-12366240)
- License Information
-
More Information
Article History
Received: 29 October 2025
Accepted: 24 February 2026
First Online: 5 March 2026
Declarations
:
: The PROSPET-BX trial has been approved by the Ethics Committee of the IRCCS Humanitas Research Hospital (ID 3131) and registered at ClinicalTrials.gov (ID NCT05297162). Written informed consent has been obtained before inclusion in the study from all participants. All procedures performed in studies involving human participants were in accordance with the Helsinki Declaration as revised in 2024 and its later amendments.
: Egesta Lopci reports receiving grant support from Fondazione AIRC (Associazione Italiana per la Ricerca sul Cancro). The remaining authors have nothing to disclose.
